Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0063)
Drug Name
Alfuzosin hydrochloride
Synonyms
Alfetim; Alfoten; Alfuzosin; Alfuzosin (hydrochloride); Alfuzosin HCl; Alfuzosin Hydrochloride; Alfuzosin hydrochloride (Uroxatral); Alfusosine; Alfuzosin [INN:BAN]; Alfuzosina; Alfuzosina [Spanish]; Alfuzosine; Alfuzosine [French]; Alfuzosinum; Alfuzosinum [Latin]; C19H27N5O4; CHEBI:51141; CHEMBL709; HSDB 7290; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide; SL 77-499; SL 77499; WNMJYKCGWZFFKR-UHFFFAOYSA-N; 81403-80-7; ALFLUZOCIN; CHEBI:32286; DSSTox_CID_25514; DSSTox_GSID_45514; DSSTox_RID_80924; MFCD00879135; SL 77 499-10; SL 77499-10; SL-77499-10; SL-7749910; Urion; Uroxatral; Uroxatral (TN); Xatral; Xatral OD; Xatral Retard; Xatral SR; Xatral XL; (+-)-N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furamide monohydrochloride; 81403-68-1
Indication Prostatic hyperplasia [ICD11: GA90] Approved [1]
Structure
3D MOL is unavailable 2D MOL
Pharmaceutical Properties Molecular Weight 425.9 Topological Polar Surface Area 112
Heavy Atom Count 29 Rotatable Bond Count 8
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 8
Cross-matching ID
PubChem CID
71764
PubChem SID
7848755 ; 8194817 ; 11528652 ; 12012888 ; 14758527 ; 43128042 ; 57318350 ; 78268148 ; 92125289 ; 92719118 ; 99004050 ; 99437262 ; 103679622 ; 103838871 ; 103914210 ; 104351250 ; 117539890 ; 124757231 ; 125164035 ; 125334025 ; 126621070 ; 126670423 ; 134223983 ; 134339185 ; 135029857 ; 135692140 ; 135698308 ; 136368114 ; 144115579 ; 144204252 ; 152106189 ; 162037591 ; 162179024 ; 163132546 ; 163564178 ; 164814685 ; 170465022 ; 175611078 ; 196110834 ; 198992200 ; 203355613 ; 210279324 ; 210281647 ; 223401659 ; 224081319 ; 226540787 ; 251912085 ; 251915158 ; 252157178 ; 252359239
ChEBI ID
CHEBI:32286
CAS Number
81403-80-7
TTD Drug ID
D0H1YQ
Formula
C19H28ClN5O4
Canonical SMILES
CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl
InChI
1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H
InChIKey
YTNKWDJILNVLGX-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Unclear DM009999 N. A. Oxidation - N-Dealkylation 1 [4]
Unclear DM009999 N. A. Oxidation - O-Demethylations 1 [4]
Unclear DM009999 N. A. Oxidation - Oxidation 1 [4]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR000127 Alfuzosin hydrochloride . Oxidation - O-Demethylations CYP3A4 [4]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Unclear metabolic mechanism (DME-unclear) DME1365 Bacteroides dorei Not Available Not Available [3]
References
1 Alfuzosin Hydrochloride was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004 Mar;2(1):14-23.
3 Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467.
4 LABEL:LFUZOSIN HYDROCHLORIDE EXTENDED RELEASE- alfuzosin hydrochloride tablet

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.